Skip to main navigation

Our Science
Pipeline & Programs
About Us
Life at Arvinas
Patients
Investors + Media

>> Sub navigation

Careers
Contact

Investors + Media: Press Releases

Press Releases

Year

November 27, 2019

Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference

November 21, 2019

Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

November 6, 2019

Arvinas, Inc. Announces Pricing of Public Offering of Common Stock

November 6, 2019

Arvinas, Inc. Announces Proposed Offering of Common Stock

November 4, 2019

Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update

October 23, 2019

Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders

October 17, 2019

Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

October 2, 2019

Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders

October 1, 2019

Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio

August 27, 2019

Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Tools

Email Alerts
RSS Feeds
Print Page
Email Page

Leading the way in targeted protein degradation therapeutics.

Join our team of experts

Follow Us https://www.linkedin.com/company/arvinas/ https://twitter.com/ArvinasInc

©2020. All Rights Reserved.

Contact Privacy Policy Terms & Conditions